Display options
Cite
Ohsugi T. A transgenic mouse model of human T cell leukemia virus type 1-associated diseases. Front Microbiol. 2013;4:49doi: 10.3389/fmicb.2013.00049.
Ohsugi, T. (2013). A transgenic mouse model of human T cell leukemia virus type 1-associated diseases. Frontiers in microbiology, 449. https://doi.org/10.3389/fmicb.2013.00049
Ohsugi, Takeo. "A transgenic mouse model of human T cell leukemia virus type 1-associated diseases." Frontiers in microbiology vol. 4 (2013): 49. doi: https://doi.org/10.3389/fmicb.2013.00049
Ohsugi T. A transgenic mouse model of human T cell leukemia virus type 1-associated diseases. Front Microbiol. 2013 Mar 08;4:49. doi: 10.3389/fmicb.2013.00049. eCollection 2013. PMID: 23483782; PMCID: PMC3592262.
Copy Download .nbib Format: NLM
Share it on

Front Microbiol. 2013 Mar 08;4:49. doi: 10.3389/fmicb.2013.00049. eCollection 2013.

A transgenic mouse model of human T cell leukemia virus type 1-associated diseases.

Frontiers in microbiology

Takeo Ohsugi

Affiliations

  1. Division of Microbiology and Genetics, Institute of Resource Development and Analysis, Kumamoto University Kumamoto, Japan.

PMID: 23483782 PMCID: PMC3592262 DOI: 10.3389/fmicb.2013.00049

Abstract

Human T cell leukemia virus type 1 (HTLV-1) is the etiological agent of adult T cell leukemia/lymphoma (ATLL) and several inflammatory diseases. Tax, the protein encoded by HTLV-1, may be responsible for the development of the diseases caused by this virus. To investigate the pathogenic role of Tax, several transgenic mouse strains expressing Tax have been developed in recent years. These mice develop various tumors including large granular lymphocytic leukemia, as well as inflammatory diseases such as arthritis. These results suggest that Tax expression alone is sufficient to cause both malignant neoplastic diseases and inflammatory diseases. However, until recently, there were no tax transgenic mice that develop T cell leukemia and lymphoma resembling ATLL. The first successful induction of leukemia in T cells was pre-T cell leukemia generated in transgenic mice in which a mouse lymphocyte-specific protein tyrosine kinase p56 (lck) (lck)-proximal promoter was used to express the tax gene in immature T cells. Subsequently, transgenic mice were established in which the lck-distal promoter was used to express Tax in mature T cells; these mice developed mature T cell leukemia and lymphoma that more closely resembled ATLL than did earlier mouse models.

Keywords: ATLL; HTLV-1; Tax; animal model; transgenic mice

References

  1. Lancet. 2001 Sep 15;358(9285):903-11 - PubMed
  2. J Virol. 2003 Sep;77(17):9716-22 - PubMed
  3. Immunity. 1996 Nov;5(5):429-36 - PubMed
  4. Mol Cell Biol. 1987 Dec;7(12):4407-13 - PubMed
  5. Nature. 1989 Sep 7;341(6237):72-4 - PubMed
  6. Nat Med. 2007 May;13(5):527-8 - PubMed
  7. Leukemia. 1997 Apr;11 Suppl 3:582-4 - PubMed
  8. Eur J Pharmacol. 2007 Mar 8;558(1-3):199-207 - PubMed
  9. Immunity. 1994 Jul;1(4):261-7 - PubMed
  10. Eur J Immunol. 1995 Jul;25(7):1877-82 - PubMed
  11. J Exp Med. 1991 Feb 1;173(2):383-93 - PubMed
  12. J Biol Chem. 2004 Jul 30;279(31):31991-4 - PubMed
  13. Eur J Immunol. 2000 Jan;30(1):8-18 - PubMed
  14. Cell. 2012 Feb 3;148(3):447-57 - PubMed
  15. Oncol Res. 2013;20(9):403-10 - PubMed
  16. PLoS Pathog. 2011 Feb 10;7(2):e1001274 - PubMed
  17. Blood. 2006 May 15;107(10):3976-82 - PubMed
  18. Blood. 2008 Nov 1;112(9):3788-97 - PubMed
  19. J Biol Chem. 2008 Aug 29;283(35):23903-13 - PubMed
  20. Immunology. 2001 Aug;103(4):407-16 - PubMed
  21. Front Microbiol. 2012 Sep 17;3:334 - PubMed
  22. Annu Rev Immunol. 2001;19:475-96 - PubMed
  23. Nature. 2003 May 15;423(6937):356-61 - PubMed
  24. Science. 1987 Sep 11;237(4820):1340-3 - PubMed
  25. Mol Cell Biol. 1992 Jun;12(6):2758-68 - PubMed
  26. J Immunol. 1998 Dec 15;161(12):6592-8 - PubMed
  27. Curr Biol. 1999 Jun 17;9(12):657-60 - PubMed
  28. J Cell Biochem. 1988 Oct;38(2):117-26 - PubMed
  29. Nat Med. 2004 Feb;10(2):197-201 - PubMed
  30. Nat Rev Cancer. 2007 Apr;7(4):270-80 - PubMed
  31. PLoS One. 2011 Apr 01;6(4):e18518 - PubMed
  32. Mol Cell Biol. 1989 May;9(5):2173-80 - PubMed
  33. Int J Hematol. 1997 Oct;66(3):257-78 - PubMed
  34. Virology. 1993 Nov;197(1):196-204 - PubMed
  35. Blood. 2001 Sep 1;98(5):1506-11 - PubMed
  36. Mol Cell Biol. 1990 Aug;10(8):4266-70 - PubMed
  37. Lancet Infect Dis. 2007 Apr;7(4):266-81 - PubMed
  38. Cancer Cell. 2009 Feb 3;15(2):103-13 - PubMed
  39. J Neurovirol. 2002 Feb;8(1):53-7 - PubMed
  40. Science. 1987 Sep 11;237(4820):1324-9 - PubMed
  41. J Virol. 2002 Dec;76(24):12813-22 - PubMed
  42. Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 - PubMed
  43. Eur J Immunol. 1995 May;25(5):1312-8 - PubMed
  44. Oncogene. 2005 Sep 5;24(39):5976-85 - PubMed
  45. Biochem Biophys Res Commun. 1989 Sep 15;163(2):1006-13 - PubMed
  46. Front Microbiol. 2012 Nov 30;3:406 - PubMed
  47. Arthritis Rheum. 1997 Jun;40(6):1096-105 - PubMed
  48. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Mar 1;14(3):272-80 - PubMed
  49. Oncogene. 2005 Sep 5;24(39):5952-64 - PubMed
  50. Science. 1994 Nov 18;266(5188):1208-12 - PubMed
  51. Annu Rev Cell Dev Biol. 2011;27:539-62 - PubMed
  52. Immunity. 1997 Jun;6(6):703-14 - PubMed
  53. Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):720-5 - PubMed
  54. Science. 1991 Aug 30;253(5023):1026-8 - PubMed
  55. J Virol. 2000 Nov;74(21):9828-35 - PubMed
  56. Oncogene. 2005 Sep 5;24(39):5931-7 - PubMed
  57. Brain. 2003 Jan;126(Pt 1):20-31 - PubMed
  58. Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1057-61 - PubMed
  59. Nat Med. 2006 Apr;12(4):466-72 - PubMed
  60. J Virol. 2007 Feb;81(4):1543-53 - PubMed
  61. Nat Rev Cancer. 2009 May;9(5):361-71 - PubMed
  62. Int Immunol. 2001 Jan;13(1):105-17 - PubMed
  63. J Immunol. 1999 Mar 1;162(5):2956-63 - PubMed

Publication Types